CNMD

In the past six months, CONMED's stock experienced several notable events. In July 2026, reports of a potential company sale led to a nearly 24% stock increase, following a BofA Securities downgrade due to growth concerns. Also in July 2026, John E. Gallagher was appointed Chief Financial Officer. On July 29, 2026, the company reported better-than-expected Q2 2026 financial results and updated full-year guidance, causing an 8.72% stock increase. In August 2026, CONMED participated in the Wells Fargo 21st Annual Healthcare Conference. By August 18, 2026, the stock had increased 38% in three months and 20.74% in one month, outperforming peers due to strong Q2 results. On October 1, 2026, CONMED announced its Q3 2026 financial results would be reported on October 28, 2026. Year-to-date 2026, the stock increased 11.4% from $40.56 to $45.1970, though some analysts noted a 27% decline due to capital weakness in international markets and increased competitive pressures.